SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET
[February 08, 2018]

Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET


CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, February 15, 2018 at 9:00 a.m. ET to discuss financial results for the fourth quarter and year end 2017. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.

Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 7396178. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.



About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea uses ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. Genocea is exploring strategic alternatives for GEN-003, its Phase 3-ready immunotherapy candidate for the treatment of genital herpes. 

For media:
Jennifer LaVin
Genocea Biosciences, Inc.
O: 207-360-0473
Jennifer.lavin@genocea.com


For investors:
Jonathan Poole
Genocea Biosciences, Inc.
O: 617-715-7795
jonathan.poole@genocea.com 

Primary Logo


[ Back To TMCnet.com's Homepage ]







Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy